Resistance to apoptosis in circulating α/β and γ/δ T lymphocytes from patients with systemic sclerosis

Journal of Rheumatology

Volumn 33, Issue 10, 2006, Pages 2003-2014

  Cipriani, Paola ^a   Fulminis, Antonietta ^a   Pingiotti, Elisa ^a   Marrelli, Alessandra ^a   Liakouli, Vasiliki ^a   Perricone, Roberto ^b   Pignone, Alberto ^c   Matucci Cerinic, Marco ^c   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

T cells; Apoptosis; Systemic sclerosis

Indexed keywords

CASPASE 3; DEXAMETHASONE; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MALE; PHENOTYPE; PRIORITY JOURNAL; SUPERNATANT; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 3; CELLS, CULTURED; DEXAMETHASONE; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGENS; PHYTOHEMAGGLUTININS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTE SUBSETS;

EID: 33749992315     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. LeRoy EC, Black C, Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Roumm AD, Whiteside TL, Medsger TA, Rodnan GP. Lymphocytes in thec skin of patients with progressive systemic sclerosis: quantification, subtyping and clinical correlations. Arthritis Rheum 1984;27:645-55.
3. Famularo G, Procopio A, Giacomelli R, et al. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990;81:368-72.
4. Needleman BW, Wigley FM, Strair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
5. Giacomelli R, Cipriani P, Danese C, et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor β1. J Rheumatol 1996;23:291-6.
6. Druet P, Shcela R, Pelletier L. Th1 and Th2 in autoimmunity. J Exp Immunol 1995;101 Suppl 1:9-12.
7. Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating, levels of soluble CD30 are increased in patients with systemic sclerosis and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997;108:42-6.
8. Yurowskv VV, Sutton PA, Schulze DH, et al. Expansion of selected Vδ1 γ/δ T cells in systemic sclerosis patients. J Immunol 1994;153:881-91.
9. Giacomelli R, Matucci-Cerinic M, Cipriani P, et al. Circulating Vδ1 T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthitis Rheum 1998;41:327-34.
10. Giacomelli R, Cipriani P, Fulminis A, et al. Circulating γ/δ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) I polarization. Clin Exp Immunol 2001;125:310-5.
11. Kahaleh MB, Fan PS, Otsuka T. γ/δ receptor hearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 1999;91:188-95.
12. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-62.
13. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1995;57:129-44.
14. Watson ML, Rao JK, Gilkerson GS, et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992;176:1645-56.
15. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
16. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
17. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
18. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORTI is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-5.
19. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature [letter]. Cell 1996;87:171.
20. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
21. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-9.
22. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
23. Pan GH, O'Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem 1998;273:5841-6.
24. Datta R, Kojima H, Banach D, et al. Activation of a CrmA insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem 1997;272:1965-70.
25. Dorstyn L, Kumar S. Differential inhibitory effects of CrmA, p35, IAP and three mammalian IAP homologues on apoptosis in NIH3T3 cells following various death stimuli. Cell Death Differ 1997;4:570-6.
26. Chao DT, Korsmeyer SJ. Bcl2 family: regulators of cell death. Ann Rev Immunol 1998;16:395-419.
27. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
28. Brady HJ. T cells from baxa transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage induced cell death in the absence of p53 gene product. EMBO J 1996;15:1221-30.
29. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998;4:1099-109.
30. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
31. Brennan P, Silman A, Black C, et al. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992; 31:457-60.
32. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
33. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J Immunol Methods 1995;184:3901.
34. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic-sclerosis. J Immunol 2002;168:3649-59.
35. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
36. Matiba B, Mariani SM, Krummer PH. The CD95 system and the death of a lymphocyte. Semin Immunol 1997;9:59-64.
37. Eischen CM, Williams BL, Zhang W, et al. ZAP-70 tyrosine kinase is required for the up-regulation of Fas ligand in activation induced T cell apoptosis. J Immunol 1997;159:1135-41.
38. Kabelitz, D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993;14:338-9.
39. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
40. Zacharchuck CM, Mercep M, Chakraboti PK, Simon SS Jr, Ashwell J. Programmed T lymphocyte death. Cell activation- and steroid induced pathways are mutually antagonistic. J Immunol 1990;145:4037-45.
41. Cifone MG, Migliorati G, Parroni R, et al. Dexamethasone induced thymocyte-apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C. acidic sphingomyelinase and caspases. Blood 1999;93:2282-96.
42. Migliorati G, Nicoletti I, D'Adamio F, Spreca A, Pagliacci C, Riccardi C. Dexamethasone induces apoptosis in mouse natural killer cells and cytotoxic T lymphocytes. Immunology 1994; 81:21-6.
43. Chen X, Murakami T, Oppenheim JJ, Howard OM. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone induced cell death. Eur J Immunol 2004;34:859-69.
44. Kabelitz D, Pechhold K, Bender A, et al. Activation and activation-driven death of human gamma/delta T cells. Immunol Rev 1991;120:71-88.
45. Kabelitz D, Wesselborg S, Pechold K, Janssen O. Activation and deactivation of cloned gamma/delta T cells. Curr Top Microbiol Immunol 1991;173:197-202.
46. Mukasa A, Lahn M, Fleming S. et al. Extensive and preferential Fas/Fas ligand-dependent death of gamma-delta T cells following infection with Listeria monocytogenes. Scand J Immunol 2002;56:233-47.
47. Lopez RD, Xu S, Guo B, Negrin RS, Waller EK. CD2-mediated IL 12-dependent signals render human γ/δ T cells resistant to mitogen induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 2000;96:3827-37.
48. Sato S, Hanakawa H, Hasegawa M, et al. Levels of interleukin 12, a cytokine of type I helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000;27:2838-42.
49. Aringer M, Wintersberger W, Steiner CW, et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-30.
50. Lorenz HM, Grunke M, Hieronymus T, et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patienls with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997;40:306-17.
51. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73:109-14.
52. Stummvoll GH, Aringer M, Smolen JS, et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology Oxford 2000;39:1341-50.
53. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996;87:847-51.
54. Weitzig T, Petri JB, Mittag M, Haustein U-F. Serum levels of soluble fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 1998;290:187-90.
55. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
56. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997;40:1126-9.
57. Christensson M, Pettersson E, Eneslatt K, et al. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 2002;22:220-7.
58. Ishimaru N, Yanagi K, Ogawa K, Suda T, Saito I, Hayashi Y. Possible role of organ-specific autoantigeu for Fas ligand-mediated activation-induced cell death in murine Sjogren's syndrome. J Immunol 2001;167:6031-7.
59. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001;28:22-8.
60. Kim S, Kim KA, Hwang DY, et al. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J Immunol 2000;164:2931-6.
61. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-9.
62. Ohta K, Iwai K, Kasahara Y, et al. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol 1995;7:1817-22.
63. Aringer M, Wintersberger W, Steiner CW, et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-30.
64. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73:109-14.
65. Ogawa N, Dang H, Kong L, Anaya JM, Liu GT, Tala, N. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjogren's syndrome. Arthritis Rheum 1996;39:1875-85.
66. Caron-Leslie LA, Evans RB, Cidlowski JA. Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulatcd apoptosis in S49 cells. FASEB J 1994;8:639-45.
67. Akbar AN, Borthwick NJ, Wickremasinghe RG, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 1996;26:294-301.
68. Woo M, Hakem A, Elia AJ, et al. In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes. J Immunol 1999;163:4909-16.
69. Martinez-Lorenzo MJ, Gamen S, Etxeberria J, et al. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells. Int J Cancer 1998;75:473-81.
70. Boatright KM, Salvesen GS. Caspase activation. Biochem Soc Symp 2003;70:233-42.
71. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
72. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-19.
73. Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N. Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 2003;134:538-44.
74. Migita K, Yamasaki S, Kita M, et al. Nitric oxide protects cultured rheumatoid synovial cells from Fas-induced apoptosis by inhibiting caspase-3. Immunology 2001;103:362-7.
75. Sciorati C, Rovere P, Ferrarini M, et al. Generation of nitric oxide by the inducible nitric oxide synthase protects gamma delta T cells from Mycobacterium tuberculosis-induced apoptosis. J Immunol 1999;163:1570-6.